Blood CancerArchives
Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019Blood Cancer 4 min.
Philadelphia‐chromosome (Ph)‐positive chronic myeloid leukemia (CML) accounts for approximately 15% of leukemias in the United States, with approximately 9000 cases diagnosed annually. Before 2000, the treatment of CML consisted of hydroxyurea, busulfan, interferon α, and allogeneic...
Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemiaBlood Cancer 8 min.
what is the new aspect of your work? This is a comprehensive review of practical approaches to optimize outcomes with CD19‐directed CAR‐T cell therapy in adults with relapsed/refractory B‐cell ALL....
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE studyBlood Cancer 4 min.
Chronic lymphocytic leukemia (CLL), the most common leukemia among adults in Western countries (incidence about 4‐5 per 100,000), primarily affects the older adult population (median age at diagnosis about 70 years), and has a higher prevalence in men. CLL is a heterogeneous B lymphocyte condition...
Clinical implications of aberrant PD-1 expression for acute leukemia prognosisBlood Cancer 4 min.
Acute leukemia (AL) is a malignant clonal disease originating from hematopoietic stem cells. Abnormal blast cells and immature cells (leukemia cells) in the bone marrow proliferate in large numbers and inhibit normal hematopoiesis. It is mainly divided into acute lymphoblastic leukemia (ALL) and acute...
Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO studyBlood Cancer 5 min.
Chronic myeloid leukemia (CML) patients in chronic phase (CP) now enjoy a normal life expectancy thanks to the routine use of tyrosine kinase inhibitors (TKIs). These drugs are able to induce not only a complete cytogenetic response (CCyR) in over 80% of subjects, but also a deep molecular response (DMR...
